CDMOs in Lithuania: 4 compared (2026)
4 of the 255 contract development and manufacturing organisations in A4BEE’s European census are headquartered in Lithuania. None has revenue over €1bn. 0 sit between €250m and €1bn and 4 are smaller or niche.
By ownership: 4 family-owned. The most common capabilities are oral solid dose (2), monoclonal antibody (2), microbial and protein (2), biologics and biosimilars (2) and viral vector and vaccine (2). 0 of the 4 rows rest on audited reports or official company disclosures; the rest come from secondary sources or estimates.
4 companies
CDMOs in Lithuania
| Company | HQ | Ownership | Size | Revenue (as reported) | Modalities | Data |
|---|---|---|---|---|---|---|
| EscolitNewer (2021) Lithuanian CMO/CDMO for medicines and supplements — three full-cycle EU-GMP lines. Early stage; contract track record still thin. | Telšiai | Family-owned | Tier 3 | not disclosed | Oral solid dose | low |
| Northway BiotechCEE cost-competitive biologics CDMO scaling to 5,000 L stainless steel. | Vilnius | Family-owned | Tier 3 | n/d | Monoclonal antibody, Microbial and protein, Biologics and biosimilars, Sterile fill-finish, Viral vector and vaccine, Cell and gene therapy | medium |
| ValentisLithuanian group offering contract manufacturing of tablets, capsules, liquids/shots and powders plus primary/secondary packaging. | Kaunas | Family-owned | Tier 3 | not disclosed | Oral solid dose | medium |
| Wellgem BiopharmaBiologics contract dev/manufacturing: mammalian + microbial cell-line/process dev, cGMP cell banking, Phase II pilot facility. Newer entrant. | Vilnius | Family-owned | Tier 3 | not disclosed | Biologics and biosimilars, Monoclonal antibody, Microbial and protein, Viral vector and vaccine, Cell and gene therapy | medium |
Size: Tier 1 (revenue over €1bn) · Tier 2 (€250m–€1bn) · Tier 3 (under €250m or niche).
Revenue, staff and site figures are as reported and mix audited accounts with commercial estimates, which are often wrong for private companies. Each row carries a confidence mark; verify a figure before quoting it.
Browse the census
Other European CDMO lists
By country
- CDMOs in Italy (31)
- CDMOs in Spain (30)
- CDMOs in Germany (28)
- CDMOs in the United Kingdom (25)
- CDMOs in France (15)
- CDMOs in Switzerland (14)
- CDMOs in Poland (11)
- CDMOs in Belgium (9)
- CDMOs in Sweden (9)
- CDMOs in Greece (8)
- CDMOs in Ireland (8)
- CDMOs in the Netherlands (8)
- CDMOs in Portugal (8)
- CDMOs in Denmark (7)
- CDMOs in Austria (5)
- CDMOs in Finland (5)
- CDMOs in Norway (5)
- CDMOs in Czechia (4)
- CDMOs in Lithuania
- CDMOs in Bulgaria (3)
By modality
- Small-molecule API CDMOs in Europe (107)
- Oral solid dose CDMOs in Europe (94)
- Sterile fill-finish CDMOs in Europe (106)
- Biologics and biosimilars CDMOs in Europe (66)
- Monoclonal antibody CDMOs in Europe (36)
- Antibody-drug conjugate (ADC) CDMOs in Europe (15)
- Cell and gene therapy CDMOs in Europe (29)
- mRNA and LNP CDMOs in Europe (22)
- Viral vector and vaccine CDMOs in Europe (32)
- Microbial and protein CDMOs in Europe (34)
- Peptide CDMOs in Europe (24)